Conformal Medical

The CLAAS implant. [Image courtesy of Conformal Medical]Conformal Medical announced “encouraging” results when comparing its CLAAS implant to the Boston Scientific Watchman FLX.

These left atrial appendage occlusion (LAAO) devices bring different things to the table. Made of foam, CLAAS features a cup design with an embedded nitinol skeleton covered by a fluoropolymer (ePTFE) cover. Watchman FLX’s nitinol frame is covered by a polyethylene terephthalate (PET).

Dr. William Gray presented an abstract on the comparison between devices at the Cardiovascular Research Technologies (CRT) 2024 conference.

The in vitro study compared the relative thrombogenicity of CLAAS compared to Watchman FLX. Investigators inserted three of each device into an acute radiolabeled in vitro blood loop system. After 90-120 minutes of exposure, investigators visually assessed the implants and measured the radiolabels.

Conformal Medical reported that CLAAS dem…

Conformal Medical today announced the successful completion of its Series D funding round, where it raised a total of $35 million.

The oversubscribed Series D was led by Sprig Equity, with participation from all major Series C investors.

“Sprig Equity is focused on enabling transformative medical technology companies to achieve meaningful milestones and, more importantly, improve the quality of human life,” said Managing Partner Evan Norton. “We see the investment in Conformal Medical as an opportunity to accelerate innovation in the LAAO market, which is of strategic importance to major medtech players.”

Nashua, New Hampshire-based Conformal Medical currently makes a left atrial appendage occlusion device. The device seals the left atrial appendage in patients with non-valvular atrial fibrillation to reduce the risk of stroke without the need for anticoagulants.

The new funding round reflects the progress and achievements …

The CLAAS implant. [Image courtesy of Conformal Medical]Conformal Medical announced today that results from an early feasibility study support the use of its CLAAS implant for reducing stroke risk.

Nashua, New Hampshire-based Conformal’s study evaluated angiography compared to transesophageal echocardiogram (TEE) in left atrial appendage (LAA) assessment. Dr. William Gray presented findings at Cardiovascular Research Technologies Conference (CRT 2023) in Washington, D.C. Gray serves as co-director of the Lankenau Heart Institute and Professor of Medicine at Thomas Jefferson University.

According to Gray, the study evaluated data from 36 AFib patients deemed appropriate for left atrial appendage occlusion (LAAO). Researchers analyzed paired images for LAA diameter and depth to facilitate CLAAS device size selection. Results demonstrated a 97% agreement in device size selection between the two imaging modalities.

About the Conformal Medical CLAAS system Read more

Stroke prevention technology developer Conformal Medical filed an SEC Form D to confirm the sale of $70 million in an equity offering.

Nashua, N.H.-based Conformal Medical is offering $85 million in equity in total, leaving $15 million left to be sold. It made the first sale in the new notice offering on July 24 and does not intend for it to last longer than one year, according to the filing.

The offering, which has no minimum investment requirement, is not being made in connection with a merger, acquisition or other similar business transaction. The company has already collected investments from 30 participants so far.

Conformal Medical did not list an intended use of proceeds. The company develops a device designed to seal off the heart’s left atrial appendage to help prevent stroke in atrial fibrillation patients.